跳到正文
今天11月8日周日2 条
  1. STAT · 医学与生命科学新闻

    美国威斯康星州报告一名婴儿感染麻疹后死亡,为该州36年来首例麻疹死亡

    美国威斯康星州卫生服务部周四宣布,该州西南部一名婴儿感染麻疹后死亡,为该州36年来即1990年以来的首例麻疹死亡。出于保护家庭隐私,官方未说明死亡发生的地点,也未提供其他细节。婴儿的感染来源、疫苗接种情况等信息原文均未给出,事件属群体层面的公共卫生通报。

11月7日周六
11月6日周五
  1. EMA · What's New

    感染病学:Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 64, Status: Authorised

    原文摘录:Comirnaty RSS Authorised This medicine is authorised for use in the European Union COVID-19 mRNA vaccine Medicine Human Authorised Rolling review Application under evaluation CHMP opinion European Commission decision Overview Comirnaty is a vaccine for pr … 5-containing Covid-19 mRNA vaccines in the Nordic countries - post-authorisation study A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU - post-authorisation study Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain) - post-authorisation study This page was last updated on 06/11/2026

  2. EMA · What's New

    感染病学:Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 34, Status: Authorised

    原文摘录:Entyvio RSS Authorised This medicine is authorised for use in the European Union vedolizumab Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Entyvio is a medicine used to treat adult patients with … 73 KB - PDF) First published: 21/03/2014 Last updated: 21/03/2014 View News on Entyvio Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021 17/12/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020 28/02/2020 European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014 10/07/2014 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014 21/03/2014 European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn's disease 21/03/2014 More information on Entyvio EMEA-000645-PIP03-18 - paediatric investigation plan EMEA-000645-PIP01-09-M09 - paediatric investigation plan EMEA-000645-PIP04-20-M02 - paediatric investigation plan Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025 - post-authorisation study Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry - post-authorisation study Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II) - post-authorisation study Comparative Effectiveness of Tofacitinib Versus Ustekinumab and Vedolizumab among Ulcerative Colitis Patients With Prior Anti- Tumor Necrosis Factor (TNF) Failure - post-authorisation study Topics Medicines This page was last updated on 06/11/2026

  3. PubMed · American Journal of Physiology-Cell Physiology

    膜片钳直接记录证实伤寒沙门菌含菌空泡膜上存在TRPML2依赖的阳离子电导(体外研究)

    研究以伤寒沙门菌感染THP-1细胞为模型,首次对含病原体空泡(SCV)膜直接进行膜片钳记录。野生型细胞SCV在负电位下呈现强内向电流,在TRPML2敲除细胞中减弱并可被TRPML2激动剂增强,且显示TRPML2依赖的Mg²⁺和Ca²⁺电导;PI3P可减缓电流衰减。该体外电生理研究为宿主-病原体界面离子通道功能研究建立了平台,未涉及患者结局。

  4. PubMed · Clinical Microbiology Reviews

    综述:新型β-内酰胺类及β-内酰胺/β-内酰胺酶抑制剂复方对抗碳青霉烯酶产酶肠杆菌目(CPE)的微生物学进展

    Clinical Microbiology Reviews发表综述,系统梳理针对碳青霉烯酶产酶肠杆菌目(CPE,涉及KPC、OXA-48-like、NDM、VIM、IMP等A、B、D类酶)的新型β-内酰胺类及β-内酰胺/β-内酰胺酶抑制剂复方。内容涵盖头孢地尔及含青霉烷砜、重氮双环辛烷和环状硼酸类抑制剂复方的结构与机制特征、体外抗菌活性及新发耐药机制,以指导临床定位和新药开发。

  5. PubMed · Journal of Economic Entomology

    综述:新大陆螺旋蝇Cochliomyia hominivorax基因组学对既往、当前与未来防控策略的启示

    这是一篇关于新大陆螺旋蝇Cochliomyia hominivorax基因组学研究的综述。该虫幼虫为专性寄生,危害美洲畜禽、野生动物及偶发人类,曾经不育昆虫技术(SIT)从北美和中美根除,但2023年起重新入侵。完整基因组已更新至第二版,遗传工程性别分离品系正在开发,基因驱动处于早期阶段,基因组学进展可为下一代防控方案提供基础。

  6. PubMed · International Journal of Biological Macromolecules

    感染病学:Valorization of pomegranate peel into active packaging films: Pectin/gelatin matrices empowered by residue-derived carbon dots for blueberry shelf-life extension.

    原文摘录:The increasing demand for sustainable food packaging technologies has stimulated the development of biomass-derived active materials capable of simultaneously reducing agricultural waste and extending food shelf life.

  7. PubMed · Cell Reports

    Cell Reports发表临床前研究:编码嵌合与马赛克血凝素的自扩增mRNA疫苗对系统发育多样的甲型流感病毒产生广谱免疫

    临床前研究显示,编码嵌合(cHA)与马赛克(mHA)血凝素的自扩增mRNA(samRNA)疫苗经初免-加强免疫后,组1疫苗(cH8/1-cH5/1)诱导广谱交叉反应抗体,对覆盖数十年抗原漂移的多种H1N1株完全保护;组2疫苗(cH4/3-cH15/3、mH10/3-mH14/3)对多种H3N2株及异亚型H7N9攻击提供类似广度,cHA samRNA跨组保护更优。

  8. PubMed · PLoS neglected tropical diseases

    美国佛罗里达州汉森病(麻风)1996–2025年流行趋势分析:年发病率从0.01升至0.15/10万,30年增长15倍

    研究者利用公开数据分析美国佛罗里达州1996–2025年汉森病(麻风)流行趋势,期间共报告359例确诊病例,年发病率从0.01/10万升至0.15/10万,增长15倍。2023年美国共报告225例新病例,佛州为主要报告州之一;Brevard县以113例成为确诊病例热点,在已知感染来源的病例中本地获得性感染占比最大。

  9. PubMed · PLoS neglected tropical diseases

    观点文章:麻风多药物治疗不能消除眼部残疾风险,呼吁建立治疗中评估与风险分层随访衔接路径

    观点文章指出,麻风联合化疗(MDT)虽可实现微生物学治愈,但不能逆转已建立的神经损伤,也不能消除未来眼部并发症风险;兔眼、角膜感觉减退、暴露性角膜病变、葡萄膜炎等可在诊断时、治疗中或治疗结束后长期出现。作者建议将治疗中眼部评估与治疗完成后的风险分层随访、明确转诊责任、支持性自我照护及视力结局常规记录相衔接,并整合入现有麻风、初级保健和眼科服务体系。

  10. PubMed · Environmental Toxicology and Chemistry

    伊维菌素对鲤鱼(Cyprinus carpio)的生物安全性与HSP70基因表达影响的动物实验研究

    一项动物实验研究评估了伊维菌素(IVM)在鲤鱼中的生物安全性,测得口服LD50为8.91±3.46 mg/kg体重。单次灌服0–5.11 mg/kg共6组观察21天,RBC、WBC、Hb、PCV、肝酶、NBT活性、血清溶菌酶和HSP70表达呈剂量依赖性应激变化,≥2.55 mg/kg应激明显,0.54 mg/kg与对照组相当,定为NOAEL,1.00 mg/kg为LOAEL。

  11. PubMed · Molecular Biology and Evolution

    感染病学:Simpler is not always better: Phylodynamic misspecification and deep-learning corrections.

    原文摘录:Phylodynamics bridges the gap between epidemiology and pathogen genetic data. The birth-death (BD) model and its extensions serve to infer the average number of secondary infections Re and the infection duration d from time-scaled pathogen phylogenies. … This motivates the use of complex epidemiologically realistic estimators, whose design has recently become possible thanks to deep learning

  12. PubMed · Biochemical Pharmacology

    感染病学:Probenecid promotes relaxation and potentiates the effects of cyclic nucleotide-elevating agents in the pig detrusor.

    原文摘录:Probenecid is a uricosuric agent also used as an antibiotic adjuvant. It inhibits, organic acid transporters (OATs), multidrug resistance-associated proteins (MRPs) and pannexin-1 (Panx-1) channels and activates transient receptor potential vanilloid 2. … These findings support further investigation of probenecid, alone or combined with clinically approved agents such as tadalafil or cilostazol, as a potential therapeutic approach for overactive bladder dysfunction

  13. PubMed · Journal of Thoracic and Cardiovascular Surgery

    主动脉瓣感染性心内膜炎主动脉根部脓肿单中心回顾研究:脓肿与不良预后相关,补片修复较扩大手术结局更佳

    一项2019–2024年单中心回顾性研究纳入158例手术治疗的主动脉瓣感染性心内膜炎患者(57%合并主动脉根部脓肿),中位随访1.22年。根部脓肿与MACCE(校正HR 3.15, 95%CI 1.51–6.59, p=0.002)及心衰再住院(SHR 4.54, 1.55–13.30, p=0.006)增加相关。

  14. PubMed · The Lancet Infectious Diseases

    Ganaplacide联合lumefantrine固体分散体治疗儿童非复杂性恶性疟的KALUMI开放标签多中心随机对照II期非劣效试验

    一项在布基纳法索、马里、科特迪瓦、加蓬和刚果(金)十家机构开展的开放标签、多中心、随机、适应性、II期非劣效试验(NCT04546633,已完成),评估ganaplacide 400 mg联合lumefantrine固体分散体治疗非复杂性恶性疟儿童(6个月至<18岁)的食物效应与非劣效性,对照artemether-lumefantrine。

11月5日周四
  1. PubMed · Emerging infectious diseases

    美国CDC分析2024年5月至2025年1月Oropouche病毒病104例特征并提出临床检测标准

    美国CDC为应对2024–2025年美洲Oropouche病毒疫情,评估了美国104例Oropouche病毒病患者特征并与266例检测阴性者比较症状组合的灵敏度与特异度。病例中发热占94%、头痛83%、肌痛78%,报告≥5种症状者65例;≥2种症状组合灵敏度99%但特异度仅7.5%,纳入旅行史后特异度升至61%。提示临床检测标准可根据监测目标调整。

  2. PubMed · Journal of Applied Microbiology

    感染病学:A microfluidic model of bacterial keratitis to quantify the efficacy of anti-infective compounds under flow.

    原文摘录:AIMS: Bacterial infections of the cornea, also known as bacterial keratitis, are a major cause of blindness. The corneal surface is protected against infection by the flow of tear fluid, which displaces potential pathogens and debris. … These findings, obtained using two widely studied model strains, illustrate how microfluidic models of infection can offer valuable insights into how flow influences bacterial keratitis and guide the development of new treatments

  3. PubMed · Blood

    感染病学:The Pathogen Recognition Receptor RIG-I is Functional in Platelets and Limits Thrombotic Responses.

    原文摘录:Influenza is associated with increased thrombotic risk, and its viral RNA (vRNA) can be sensed by pattern-recognition receptor RIG-I, but the function of RIG-I in platelets remains unknown. … Our study is the first to demonstrate that platelets have a functionally active vRNA-sensing RIG-I receptor that finely tunes thrombotic risk and facilitates appropriate leukocyte transmigration during infection, through non-classical platelet activation

    关注理由:这篇感染病学资料可用于了解领域进展,研究设计、结果和局限性值得一起阅读。

  4. PubMed · Critical Care Medicine

    感染病学:Long-Term Mortality in Sepsis Survivors: A Population-Based Study During 15 Years.

    原文摘录:OBJECTIVES: To evaluate long-term mortality among sepsis survivors in Catalonia over a 15-year period and to identify factors associated with increased mortality within 2 years after hospital discharge. DESIGN: Retrospective population-based cohort study.

    关注理由:这篇感染病学队列研究资料适合了解长期变化,研究对象、随访方式和结局指标建议一起查看。

  5. PubMed · The Lancet Infectious Diseases

    病例报告:特立妥单抗(teclistamab)治疗骨髓瘤患者发生淋巴细胞脉络丛脑膜炎病毒脑膜脑炎,联合抗病毒治疗改善

    《The Lancet Infectious Diseases》报道英国一例复发多发性骨髓瘤患者在接受双特异性抗体teclistamab治疗后发生淋巴细胞脉络丛脑膜炎病毒(LCMV)脑膜脑炎,经脑脊液宏基因组二代测序确诊,并有家养啮齿类动物接触史。

11月4日周三
  1. PubMed · Science Translational Medicine

    VRC01抗体预防HIV-1感染随访至104周:敏感毒株获保护后出现耐药突破感染

    研究团队分析AMP两项平行试验至104周最终访视的HIV-1获得情况:静脉输注广谱中和抗体VRC01后,对VRC01高度敏感(IC80<阈限)的病毒感染被阻断,而随着体内VRC01浓度下降,在药物选择压力下 evolved 出更强耐药性的病毒以可检出的突破感染出现(VRC01组11例对安慰剂组1例)。结果提示单株抗体只能阻断敏感株,预防病毒逃逸与突破感染可能需要多种抗体联合。